

# Routine immunization profile Germany

## Progress towards achieving European Vaccine Action Plan goals, 2017

Goal	Indicator	Status	Goal	Indicator	Status
<b>1</b>	Sustain polio-free status <sup>a</sup> (Current risk)	Yes (Intermediate)	<b>4</b>	Meets vaccination coverage targets DTP3 national immunization coverage $\geq 95\%$ <sup>d</sup> $\geq 90\%$ DTP3 coverage achieved in $\geq 90\%$ of districts <sup>e</sup>	No Yes ND
<b>2</b>	Measles elimination status <sup>b</sup>	Endemic	<b>5</b>	Make evidence-based decisions about introduction of new vaccines* <sup>e</sup> NITAG made a recommendation about PCV NITAG made a recommendation about RV NITAG made a recommendation about HPV	Yes
	Rubella elimination status <sup>b</sup>	Endemic			Yes Yes Yes
<b>3</b>	Control hepatitis B infection <sup>c</sup>	Validation pending			<b>6</b>

\*New vaccines introduced or not introduced based on NITAG evidence-based recommendations

\*\*Country self-sufficient for procuring routine vaccines

## Demographic, income and health expenditure summary, 2017

Total Population <sup>f</sup>	82 114 224
Live births	724 607
Surviving infants	722 969
<5 years	3 595 119
<15 years	10 736 390
Neonatal mortality rate (per 1000 live births) <sup>f</sup>	2.2
Infant mortality rate (per 1000 live births) <sup>f</sup>	3.1
Number of districts <sup>e</sup>	402
GNI (per capita, in USD) <sup>g</sup>	43 700
Health spending as % of total government expenditure <sup>g</sup>	21

## Immunization schedule, 2017<sup>e</sup>

6W	Rotavirus
2M	DTaP, DTaPHibHepBIPV, DTaPHibIPV, HepB_Pediatric, PCV
10W	Rotavirus
3M	DTaP, DTaPHibHepBIPV, DTaPHibIPV
4M	DTaP, DTaPHibHepBIPV, DTaPHibIPV, HepB_Pediatric, PCV
11-14M	DTaP, DTaPHibHepBIPV, DTaPHibIPV, HepB_Pediatric, MMR, PCV, Varicella
11-23M	MenC_conj
15-23M	MMR, MMRV, Varicella
5-7Y	TdaPIPV
9-14Y	HPV(2x)
9-17Y	DTaPIPV, TdaPIPV




### Vaccine coverage estimates, 2013-2017<sup>d</sup>


	2013	2014	2015	2016	2017
BCG	NR	NR	NR	NR	NR
HepB-BD	NR	NR	NR	NR	NR
DTP1	99	99	99	99	99
DTP3	95	95	95	95	95
HepB3	87	87	87	87	87
Hib3	93	93	93	93	93
Pol3	94	94	94	94	94
PCV3	84	84	84	84	84
Rotac	NR	67	68	68	68
RCV1	97	96	97	97	97
MCV1	97	97	97	97	97
MCV2	93	93	93	93	93

100 50 0 ND NR


### DTP3 reported coverage by subnational area<sup>†</sup>, 2017<sup>e</sup>



### MCV1 reported coverage by subnational area<sup>†</sup>, 2017<sup>e</sup>



### MCV2 reported coverage by subnational area<sup>†</sup>, 2017<sup>e</sup>



### Number of reported cases of vaccine-preventable diseases, 2013-2017<sup>e,i</sup>


	2013	2014	2015	2016	2017
Measles	1771	443	2464	326	929
Mumps	ND	837	699	741	652
Rubella	ND	151	90	95	74
Congenital rubella syndrome	1	0	0	0	0
Diphtheria	4	9	14	9	11
Tetanus	ND	ND	ND	ND	ND
Pertussis	ND	12 260	9000	13 809	16 183
Hepatitis A	779	681	856	736	1232
Varicella	ND	22 128	23 130	25 027	22 206

### Surveillance with laboratory confirmation of cases, 2017<sup>e,i</sup>


Measles	Yes
Rubella	Yes
Congenital rubella syndrome	Yes
Rotavirus	Yes
Invasive meningococcal disease	Yes
Invasive pneumococcal disease	No
Invasive <i>Haemophilus influenzae</i> disease	Yes

Note: Case-based surveillance (with laboratory confirmation of cases) assessed for measles, rubella, and congenital rubella syndrome. Hospital-based sentinel surveillance and/or population-based surveillance (both with laboratory confirmation of cases) assessed for rotavirus, invasive meningococcal disease, invasive pneumococcal disease, and invasive *Haemophilus influenzae* disease.


### Number of reported measles, mumps and rubella cases<sup>e</sup> and MCV coverage estimates<sup>d</sup>, 2013-2017




### Number of reported diphtheria, tetanus and pertussis cases<sup>e,i</sup> and DTP3 coverage estimates<sup>d</sup>, 2013-2017




### Reported target population, reported number of DTP4 doses administered and DTP4 reported coverage<sup>e</sup>, 2013-2017



### Percentage of districts by DTP3 reported coverage<sup>e</sup>, 2013-2017



### DTP1-DTP3 dropout rate, 2013-2017<sup>d</sup>



Note: Dropout rate is calculated using WUENIC


### Immunization system characteristics, 2017

Sustained access to WHO accredited polio, measles, and rubella laboratories <sup>h</sup>	Yes
NITAG in place that meets six WHO criteria <sup>e</sup>	Yes
National system in place to monitor AEFIs <sup>e</sup>	Yes
Communication plan in place to respond to vaccine safety-related events <sup>e</sup>	No
Vaccine hesitancy assessment performed within last 5 years <sup>e</sup>	Yes
Mandatory proof of immunization at school entry <sup>e</sup>	No

Note: The six WHO NITAG criteria are 1. legislative or administrative basis for the advisory group; 2. formal written terms of reference; 3. at least five different areas of expertise represented among core members; 4. at least one meeting per year; 5. circulation of the agenda and background documents at least one week prior to meetings; 6. mandatory disclosure of any conflict of interest

## Vaccine stockouts by administrative level<sup>a</sup>, 2013-2017

	2013	2014	2015	2016	2017
BCG	NR	NR	NR	NR	NR
DTP	ND	ND	No	ND	No
HepB	ND	ND	No	No	No
Hib	ND	ND	No	No	No
Pneumo	ND	ND	No	No	No
Rota	ND	ND	No	No	No
OPV	NR	NR	NR	NR	NR
IPV	ND	ND	No	ND	No
Measles	ND	ND	No	No	No
HPV	*	*	*	No	No
TT	ND	ND	ND	No	No



\*Data on HPV stockouts have only been collected in JRF since 2016

## Abbreviations

AEFI	Adverse event following immunization	MCV	measles-containing vaccine
BCG	Bacille Calmette-Guerin vaccine for tuberculosis	MCV1	measles-mumps-rubella vaccine, first dose
CRS	congenital Rubella Syndrome	MCV2	measles-mumps-rubella vaccine, second dose
DT	diphtheria-tetanus-containing vaccine	MMR	measles-mumps-rubella vaccine
DTP	diphtheria-tetanus-pertussis-containing vaccine	ND	Data not available
DTP1	diphtheria-tetanus-pertussis-containing vaccine, first dose	NITAG	National Immunization Technical Advisory Group
DTP3	diphtheria-tetanus-pertussis-containing vaccine, third dose	NR	Not relevant as vaccine not included in immunization schedule
DTP4	diphtheria-tetanus-pertussis-containing vaccine, fourth dose	OPV	oral polio vaccine
GNI	Gross national income	PCV	pneumococcal conjugate vaccine
HepB	hepatitis B	PCV3	pneumococcal conjugate vaccine , third dose
HepB3	hepatitis B vaccine, third dose	Pol3	polio-containing vaccine, third dose
HepB-BD	hepatitis B vaccine, birth dose	RCV1	rubella-containing vaccine, first dose
Hib	Haemophilus influenzae type b	Rotac	rotavirus vaccine-complete series
Hib3	Haemophilus influenzae type b vaccine, third dose	Td	tetanus-diphtheria-containing vaccine
HPV	human papillomavirus	TT	tetanus toxoid vaccine
IPV	inactivated polio vaccine	W,M,Y	Weeks, Months, Years

## Data sources

- European Regional Commission for Certification of Poliomyelitis eradication (RCC) meeting report: [www.euro.who.int/32ndRCC](http://www.euro.who.int/32ndRCC)
- European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: [www.euro.who.int/7thRVC](http://www.euro.who.int/7thRVC)
- European Vaccine Action Plan 2015-2020 Midterm report
- WHO/UNICEF Estimates of National Immunization Coverage (WUENIC): ([http://www.who.int/immunization/monitoring\\_surveillance/data/en/](http://www.who.int/immunization/monitoring_surveillance/data/en/))
- WHO/UNICEF Joint Reporting Form on immunization (JRF)
- World Population Prospects: The 2017 Revision, New York, United Nations
- World Bank, World Development Indicators
- Polio Laboratory Network: [www.euro.who.int/poliolabnetwork](http://www.euro.who.int/poliolabnetwork) & Personal communication based on annual accreditation process of the European Measles and Rubella Laboratory Network
- Communication with the country

## Map disclaimer

† The boundaries and names shown and the designations used on the maps do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.